Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Global Brain
AI-generated illustration
OrganisationJP

Global Brain

Tokyo venture firm that manages TOHO Ventures, a new backer of Oyster Therapeutics in 2026.

Last refreshed: 14 November 2026

Key Question

Why are Japanese investors backing British Alzheimer's biotech?

Timeline for Global Brain

#17 10 Nov

Oyster brings Eli Lilly into $60m round

UK Startups and Innovation
View full timeline →

Background

Global Brain, a Tokyo venture capital firm, manages TOHO Ventures, which joined Oyster Therapeutics' $60m Series A on 10 November 2026 as a new investor. London's 4BIO Capital led the round and Eli Lilly joined as a strategic investor.

Oyster's investor list spans Britain, the United States and Japan. Brain-disease biotech needs that breadth, because few specialist funds will carry a programme alone to first human data.

Global Brain runs funds of its own and manages corporate venture funds on behalf of other companies.

Common Questions
Who manages TOHO Ventures?
Global Brain, a Tokyo venture capital firm. TOHO Ventures joined Oyster Therapeutics' $60m Series A in November 2026.Source: BioIndustry Association
Who invested in Oyster Therapeutics?
4BIO Capital led the $60m Series A; Eli Lilly, TOHO Ventures and others joined as new investors.Source: BioIndustry Association
Where is Global Brain based?
In Tokyo, Japan.Source: Global Brain
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.